New Report: Cayman Islands Enhances Global Innovation and Economic Development Without Tax Harm
13.10.2021 10:00:00 EEST | Business Wire | Press release
Cayman Finance today is releasing “Cayman: Engine of Growth and Good Governance,” a new report that documents how the jurisdiction’s unique combination of tax neutrality, high-quality legal and regulatory system, and professional expertise attract Collective Investment Vehicles (CIVs) and Multinational Enterprises (MNEs), providing economic benefits to other jurisdictions without posing tax harm.
Trade and investment are engines of innovation and growth. Underpinning both are effective institutions: good governance (especially, political stability and the rule of law), a high-quality legal system that protects owners of assets, and effective and adaptive legislation and regulation. This new report has been commissioned by Cayman Finance to help clarify how the Cayman Islands has successfully combined all of these attributes with others that make it unique to international investors, to help drive the international economy and facilitate global economic growth.
“This report documents how the Cayman Islands’ pure tax neutrality and commitment to good governance enable investors to pool capital securely and transparently and pursue investment opportunities that drive economic growth, create jobs and generate tax revenue in countries around the world,” said Jude Scott, the CEO of Cayman Finance. “As this research shows, Cayman also poses no tax harm to other jurisdictions due to its tax neutral regime and early adoption of tax information exchange agreements, Common Reporting Standards (CRS), and other elements of the OECD’s Base Erosion and Profit Shifting (BEPS) project.”
Cayman’s approach has a competitive advantage. While some jurisdictions offer some similar attributes, a key reason that both collective investment vehicles (CIVs) and multinational enterprises (MNEs) choose to domicile entities in Cayman rather than elsewhere is that Cayman offers true tax neutrality at minimal cost. By contrast, many other jurisdictions are at best able only to facilitate a facsimile of tax neutrality through the use of special structures and double taxation treaties; moreover, these special structures are highly limiting and come with additional costs.
“Cayman: Engine of Growth and Good Governance” combines a detailed review of scholarly research and publications from the EU, OECD, IMF, FATF, UNCTAD, and other national and international bodies. Key findings include:
- CIVs and MNEs choose to domicile entities in Cayman rather than in other jurisdictions because Cayman offers pure tax neutrality at minimal cost in a well-regulated legal environment.
- Cayman and other tax neutral financial centres benefit developed jurisdictions like the EU as well as less developed countries by facilitating the provision of trillions of dollars of funding to infrastructure and other projects, increasing economic activity and innovation.
- Cayman’s pure tax neutrality enables entities to avoid double and triple taxation, facilitating greater levels of economic activity in the EU and elsewhere than would otherwise be the case. Due to Cayman’s commitment to information sharing, this activity is transparently reported to tax authorities in EU member states and other jurisdictions and leads to increased government revenue through a wide range of taxes.
“Tax neutrality is not tax avoidance. A tax neutral jurisdiction does not add an extra layer of tax on top of what investors and companies owe in their own jurisdictions in compliance with their domestic tax rules. This report demonstrates that as part of the international financial system Cayman is a transparent and globally responsible partner that improves access to capital in the US, UK, EU and other developed and developing countries,” said Mr Scott. “Moreover, it shows that International standards-setting and policy-making efforts should recognise and support the beneficial contributions to economic growth CIVs and MNEs domiciled in Cayman make globally.”
A “Cayman: Engine of Growth and Good Governance” was authored by leading economist Julian Morris and is available, along with other Cayman Finance reports, at www.caymanfinance.ky.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005314/en/
Contact information
Travis Webster
enquiries@caymanfinance.ky
+1 (345) 769-6200
@CaymanFinance
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
